<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Cluster headache: Treatment and prognosis</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Cluster headache: Treatment and prognosis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Cluster headache: Treatment and prognosis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Arne May, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jerry W Swanson, MD, MHPE</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Richard P Goddeau, Jr, DO, FAHA</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 05, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Cluster headache belongs to the trigeminal autonomic cephalalgias (TACs), a group of idiopathic headache disorders characterized by unilateral headaches accompanied by ipsilateral cranial autonomic symptoms.</p><p>The TACs include cluster headache, paroxysmal hemicrania, short-lasting unilateral neuralgiform headache attacks, and hemicrania continua. Cluster headache is the most common form.</p><p>The treatment and prognosis of cluster headache are discussed here. The epidemiology, clinical features, and diagnosis of cluster headache are discussed separately. (See  <a class="medical medical_review" href="/d/html/3326.html" rel="external">"Cluster headache: Epidemiology, clinical features, and diagnosis"</a>.)</p><p>Other TACs are discussed elsewhere.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/3334.html" rel="external">"Paroxysmal hemicrania: Clinical features and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/3335.html" rel="external">"Paroxysmal hemicrania: Treatment and prognosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/3336.html" rel="external">"Short-lasting unilateral neuralgiform headache attacks: Clinical features and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/3338.html" rel="external">"Short-lasting unilateral neuralgiform headache attacks: Treatment and prognosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/3342.html" rel="external">"Hemicrania continua"</a>.)</p><p></p><p class="headingAnchor" id="H2116545750"><span class="h1">APPROACH TO THERAPY</span><span class="headingEndMark"> — </span>Acute therapy is useful for aborting individual attacks of cluster headache but does not reduce the duration of the cluster headache bout (ie, the period of recurrent attacks) [<a href="#rid1">1</a>]. Therefore, preventive therapy should be started without delay once a cluster headache bout begins.</p><p>Currently, the treatment of cluster headache is based on empirical data rather than a clear understanding of the biologic mechanisms that underlie the disease [<a href="#rid2">2,3</a>]. Drug treatment in cluster headache shows a placebo rate of about 30 percent, similar to that observed in migraine treatment [<a href="#rid4">4</a>]. In general, cluster headache treatment can be divided into acute therapy aimed at aborting individual attacks and prophylactic therapy aimed at preventing recurrent attacks during the cluster period  (<a class="graphic graphic_table graphicRef65541" href="/d/graphic/65541.html" rel="external">table 1</a>) [<a href="#rid5">5</a>].</p><p class="headingAnchor" id="H2157482804"><span class="h2">Acute headache treatment</span><span class="headingEndMark"> — </span>For patients with acute cluster headache, we recommend initial treatment with either 100 percent oxygen or a triptan, in agreement with national guidelines and expert consensus  (<a class="graphic graphic_algorithm graphicRef140576" href="/d/graphic/140576.html" rel="external">algorithm 1</a>) [<a href="#rid1">1,6</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>Oxygen should be tried first if available (eg, in a hospital or emergency clinic setting) since it is without side effects (see <a class="local">'Oxygen'</a> below)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Otherwise, a triptan such as <a class="drug drug_general" data-topicid="9968" href="/d/drug information/9968.html" rel="external">sumatriptan</a> or <a class="drug drug_general" data-topicid="10233" href="/d/drug information/10233.html" rel="external">zolmitriptan</a> can be used as initial therapy (see <a class="local">'Triptans'</a> below)</p><p></p><p>For patients taking a triptan who are unable to administer or tolerate subcutaneous injections, we suggest treatment with intranasal triptans. Choices include intranasal <a class="drug drug_general" data-topicid="9968" href="/d/drug information/9968.html" rel="external">sumatriptan</a> 20 mg or intranasal <a class="drug drug_general" data-topicid="10233" href="/d/drug information/10233.html" rel="external">zolmitriptan</a> (5 mg). Intranasal triptans are administered <strong>contralateral</strong> to the side of headache. Intranasal triptan treatment has a slower onset of action than subcutaneous injection but is more convenient to use [<a href="#rid6">6</a>].</p><p>For patients who do not respond to or tolerate initial acute therapy with oxygen and/or triptans, alternative choices include intranasal <a class="drug drug_general" data-topicid="9558" href="/d/drug information/9558.html" rel="external">lidocaine</a>, oral <a class="drug drug_general" data-topicid="9416" href="/d/drug information/9416.html" rel="external">ergotamine</a>, and intravenous <a class="drug drug_general" data-topicid="9363" href="/d/drug information/9363.html" rel="external">dihydroergotamine</a>:</p><p class="bulletIndent1"><span class="glyph">●</span>Indirect evidence suggests that intranasal <a class="drug drug_general" data-topicid="9558" href="/d/drug information/9558.html" rel="external">lidocaine</a> for acute cluster headache is less effective than triptan treatment. However, it is easy to administer and generally lacks systemic side effects. (See <a class="local">'Lidocaine'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Oral <a class="drug drug_general" data-topicid="9416" href="/d/drug information/9416.html" rel="external">ergotamine</a> may be effective for acute cluster headache, based upon clinical experience, and has the benefit of a longer half-life than triptans, making it an alternative that can be used as a short-term preventive treatment (evening dosage) for attacks that occur only at night. Intravenous <a class="drug drug_general" data-topicid="9363" href="/d/drug information/9363.html" rel="external">dihydroergotamine</a> may also be effective for acute cluster headache, based upon retrospective data. Note that ergots should <strong>not</strong> be given to patients who have received a triptan within the preceding 24 hours and are contraindicated in pregnancy. (See <a class="local">'Ergots'</a> below.)</p><p></p><p class="headingAnchor" id="H690024775"><span class="h2">Headache prevention</span><span class="headingEndMark"> — </span>Preventive therapy should be started without delay at the onset of a cluster episode  (<a class="graphic graphic_algorithm graphicRef140577" href="/d/graphic/140577.html" rel="external">algorithm 2</a>). The goal is to suppress attacks over the expected duration of the cluster period. An effective preventive regimen is of utmost importance because patients typically have one to eight cluster headaches a day, and repeated use of abortive medications may result in toxicity and/or rebound.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Verapamil</strong><strong> </strong>– We recommend initial preventive therapy with <a class="drug drug_general" data-topicid="10043" href="/d/drug information/10043.html" rel="external">verapamil</a> for patients with chronic cluster headache (ie, continuous headaches or remission intervals of &lt;3 months) and those with episodic cluster headache with relatively long-lasting active periods (ie, four weeks or longer) [<a href="#rid1">1,6</a>]. (See <a class="local">'Verapamil plus glucocorticoids for patients with frequent attacks'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Glucocorticoids </strong>– For patients with episodic cluster headache whose active cluster periods are infrequent and last less than four weeks, we suggest initial preventive therapy with glucocorticoids alone. Glucocorticoids can rapidly suppress cluster attacks during the time required for the longer-acting preventive agents to take effect. Because of their potential for systemic side effects, glucocorticoids should only be used for short-term prophylaxis. (See <a class="local">'Glucocorticoids for patients with infrequent attacks'</a> below.)</p><p></p><p class="bulletIndent1">Due to the relatively long time needed to titrate <a class="drug drug_general" data-topicid="10043" href="/d/drug information/10043.html" rel="external">verapamil</a> to an effective dose, glucocorticoids (or <a class="drug drug_general" data-topicid="9363" href="/d/drug information/9363.html" rel="external">dihydroergotamine</a> where available) may also be used as adjunctive therapy in the first two weeks of verapamil administration. An alternative is greater occipital nerve block ipsilateral to the headache attacks. (See <a class="local">'Greater occipital nerve blocks'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Combination therapy </strong>– Although there is no high-quality evidence supporting the utility of combining various prophylactic drug treatments in cluster headache, clinical experience suggests that some patients do better with a combination of preventive medications rather than high-dose monotherapy. In most instances of combined therapy, <a class="drug drug_general" data-topicid="10043" href="/d/drug information/10043.html" rel="external">verapamil</a> is given in moderate doses (240 to 480 mg daily) in conjunction with another prophylactic medication, such as <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a>, <a class="drug drug_general" data-topicid="10006" href="/d/drug information/10006.html" rel="external">topiramate</a>, or <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a>. (See <a class="local">'Alternative preventive therapies'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Alternative options </strong>– Oral <a class="drug drug_general" data-topicid="9416" href="/d/drug information/9416.html" rel="external">ergotamine</a> has a relatively long half-life compared with triptans and can be used as preventive treatment (evening dosage) for attacks that occur only at night. (See <a class="local">'Ergots'</a> below.)</p><p></p><p class="bulletIndent1">When chronic cluster headache is unresponsive to medical treatments, various surgical interventions and neurostimulation techniques are potential treatment options, though none are clearly established as effective. In such cases, it is particularly important to exclude potential causes of secondary cluster headache. Neurostimulation techniques, including sphenopalatine ganglion stimulation and vagus nerve stimulation, appear promising but remain investigational. Destructive surgical procedures are unproven and should be viewed with great caution. (See <a class="local">'Surgery and neurostimulation'</a> below.)</p><p></p><p>For patients with episodic cluster headache, prophylactic medications should be tapered after the expected duration of the cluster has passed. For patients with chronic cluster headache who have a good response to preventive pharmacotherapy, we suggest a dose reduction trial of preventive medications every three months. The drugs can be restarted at the lowest effective dose if symptoms recur.</p><p class="headingAnchor" id="H3"><span class="h1">ACUTE INTERVENTIONS</span></p><p class="headingAnchor" id="H877288636"><span class="h2">Initial acute therapy</span><span class="headingEndMark"> — </span>We suggest initial treatment with oxygen inhalation for patients with acute cluster headache attack  (<a class="graphic graphic_algorithm graphicRef140576" href="/d/graphic/140576.html" rel="external">algorithm 1</a>) [<a href="#rid7">7</a>]. If oxygen is not effective or readily available, triptans (eg, subcutaneous <a class="drug drug_general" data-topicid="9968" href="/d/drug information/9968.html" rel="external">sumatriptan</a>) are an effective alternative initial treatment option and may be more convenient for some patients with no contraindications.</p><p class="headingAnchor" id="H4"><span class="h3">Oxygen</span><span class="headingEndMark"> — </span>Although controlled trial evidence is limited [<a href="#rid8">8</a>], oxygen therapy is considered to be safe and effective for aborting cluster headache [<a href="#rid6">6,8,9</a>].</p><p>A double-blind randomized trial evaluated 76 patients, each treating four cluster headache attacks, and compared pure oxygen therapy (at 12 L/minute for 15 minutes) with air placebo [<a href="#rid10">10</a>]. By intention-to-treat analysis, pain-free status or adequate relief of attacks at 15 minutes was significantly more frequent with oxygen (78 percent of attacks versus 20 percent with placebo). Smaller randomized trials have also found that inhalation of pure oxygen is beneficial for acute cluster headache attacks [<a href="#rid11">11-14</a>].</p><p>In some patients, oxygen may be completely effective even when the pain is at maximal intensity, but in other cases the response is incomplete. Repeated or frequent oxygen intake in a short period of time should be avoided because there is evidence that the attack frequency may increase in some patients with overuse of oxygen [<a href="#rid5">5</a>].</p><p>Oxygen (100 percent) is administered via a nonrebreathing facial mask with a flow rate of at least 12 L/minute with the patient in a sitting, upright position [<a href="#rid5">5</a>]. The inhalation should continue for 15 minutes to prevent the attack from returning, although the pain may subside as soon as five minutes after starting oxygen. Higher oxygen flow rates, up to 15 L/minute, may sometimes be effective when standard rates are not [<a href="#rid15">15</a>]. From a practical standpoint, it is reasonable to increase the flow rate if a lower rate is ineffective, as higher flow rate does not increase the risk of side effects. The use of a demand valve mask may enhance the efficacy of oxygen [<a href="#rid16">16</a>].</p><p>Oxygen is generally safe and without side effects. However, patients with severe chronic obstructive pulmonary disease should not be treated with inhaled oxygen because of the risk for developing severe hypercapnia and CO<sub>2</sub> narcosis.</p><p>Unlike normobaric oxygen therapy, hyperbaric oxygen is not widely available, and there are few studies evaluating its utility for abortive treatment of cluster headache [<a href="#rid13">13,17</a>].</p><p class="headingAnchor" id="H5"><span class="h3">Triptans</span><span class="headingEndMark"> — </span>Randomized, double-blind, placebo-controlled trials have established that triptans, particularly <a class="drug drug_general" data-topicid="9968" href="/d/drug information/9968.html" rel="external">sumatriptan</a> and <a class="drug drug_general" data-topicid="10233" href="/d/drug information/10233.html" rel="external">zolmitriptan</a>, are effective for the acute treatment of cluster headache [<a href="#rid18">18</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>In trials involving a combined total of 183 patients with cluster headache, subcutaneous <a class="drug drug_general" data-topicid="9968" href="/d/drug information/9968.html" rel="external">sumatriptan</a> (6 mg) was beneficial (ie, pain-free within 20 minutes) in about 75 percent of patients, whereas the response rate for placebo was 25 to 35 percent [<a href="#rid19">19,20</a>]. Sumatriptan was safe with no evidence of tachyphylaxis or rebound in most patients, even after frequent use [<a href="#rid21">21</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Intranasal <a class="drug drug_general" data-topicid="9968" href="/d/drug information/9968.html" rel="external">sumatriptan</a> is effective for acute cluster headache. A randomized trial of 118 patients found a significantly higher response rate at 30 minutes with sumatriptan (20 mg) compared with placebo (57 versus 26 percent) and a higher 30 minute pain-free rate (47 versus 18 percent) [<a href="#rid22">22</a>]. Although the intranasal route is more convenient, the speed of response with intranasal sumatriptan in this study was slower than that seen with subcutaneous sumatriptan in other studies.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Intranasal <a class="drug drug_general" data-topicid="10233" href="/d/drug information/10233.html" rel="external">zolmitriptan</a> is another beneficial treatment option. In a randomized trial involving 69 patients available for intention-to-treat analysis, intranasal zolmitriptan at a dose of 5 or 10 mg was modestly effective at 30 minutes for acute cluster headache compared with placebo [<a href="#rid23">23</a>]. Similar results were observed in a second trial involving 52 patients [<a href="#rid24">24</a>]. Of note, the intranasal dose of 10 mg of zolmitriptan has not been approved by the US Food and Drug Administration and is not generally available [<a href="#rid1">1</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Oral <a class="drug drug_general" data-topicid="10233" href="/d/drug information/10233.html" rel="external">zolmitriptan</a> 10 mg was modestly effective for acute episodic (but not chronic) cluster headache within 30 minutes in another placebo-controlled trial [<a href="#rid25">25</a>].</p><p></p><p class="headingAnchor" id="H2317372543"><span class="h4">Dosing and adverse effects</span><span class="headingEndMark"> — </span>Triptans should be administered as soon as the headache begins, since early treatment is likely to be more effective. Subcutaneous <a class="drug drug_general" data-topicid="9968" href="/d/drug information/9968.html" rel="external">sumatriptan</a> is administered by injection in areas with adequate skin and subcutaneous thickness (eg, the abdomen, thighs, and upper arms). The injection site should be rotated to reduce the risk of local reactions.</p><p>With subcutaneous <a class="drug drug_general" data-topicid="9968" href="/d/drug information/9968.html" rel="external">sumatriptan</a>, a 3 mg dose is effective for some patients; the maximum single dose is 6 mg. Although the label for subcutaneous sumatriptan indicates that the dose may be repeated at one hour or more if needed, it is best to repeat the dose no sooner than two hours after the initial dose, since the attack frequency of cluster headache typically ranges between two and six per day. The repeat dose is generally the same strength in mg as the initial dose. The recommended maximum cumulative dose of subcutaneous sumatriptan is 12 mg in 24 hours, but some patients with frequent headaches may require more, as discussed below.</p><p>Intranasal triptans are administered <strong>contralateral</strong> to the pain side because patients with cluster headache and other trigeminal autonomic cephalalgias often have rhinorrhea or nasal congestion ipsilateral to the pain. The dose of intranasal triptan may be repeated once if needed at ≥2 hours.</p><p>While triptans are generally well tolerated, uncomfortable side effects include nonischemic chest pain and distal paresthesia. It is still recommended that triptans be avoided in patients with ischemic cardiovascular disease or stroke, Prinzmetal angina, or uncontrolled arterial hypertension. It may be prudent to give the first triptan dose under medical supervision for patients with risk factors but no known coronary heart disease. (See  <a class="medical medical_review" href="/d/html/3347.html" rel="external">"Acute treatment of migraine in adults", section on 'Triptans'</a>.)</p><p>Because of concerns about potential adverse effects, including medication overuse headache, some experts (and the drug label) recommend that subcutaneous <a class="drug drug_general" data-topicid="9968" href="/d/drug information/9968.html" rel="external">sumatriptan</a> 6 mg should be limited to no more than two doses in 24 hours and intranasal sumatriptan 20 mg to no more than two doses (40 mg) in 24 hours [<a href="#rid26">26</a>]. However, cluster headache attacks may occur more often than twice a day, underlining the need to start preventative medicine early. Until there has been sufficient time for the patient's preventative medication to take effect, more than two triptan doses per day may be required and should be prescribed [<a href="#rid5">5,27</a>]. Tachyphylaxis with recurrent use of triptans seems to be rare in cluster headache [<a href="#rid27">27,28</a>].</p><p class="headingAnchor" id="H3015405615"><span class="h2">Alternative acute therapies</span><span class="headingEndMark"> — </span>For patients who do not tolerate or respond to initial therapies, we suggest alternative agents such as <a class="drug drug_general" data-topicid="9558" href="/d/drug information/9558.html" rel="external">lidocaine</a>, ergots, or <a class="drug drug_general" data-topicid="9714" href="/d/drug information/9714.html" rel="external">octreotide</a>. We use patient risk factors and comorbid conditions to help select among these options.</p><p class="headingAnchor" id="H8"><span class="h3">Lidocaine</span><span class="headingEndMark"> — </span>Small studies suggest that intranasal <a class="drug drug_general" data-topicid="9558" href="/d/drug information/9558.html" rel="external">lidocaine</a> is effective in at least one-third of patients, although the degree of benefit is modest [<a href="#rid29">29-33</a>].</p><p>Intranasal <a class="drug drug_general" data-topicid="9558" href="/d/drug information/9558.html" rel="external">lidocaine</a> (1 mL) is administered <strong>ipsilateral</strong> to the pain in a 4 percent topical solution [<a href="#rid5">5</a>]. The head position should be in extension by 45 degrees and rotated toward the symptomatic side by 30 to 40 degrees. Lidocaine nasal sprays are not commercially available in the United States but may be prepared by a compounding pharmacy.</p><p class="headingAnchor" id="H9"><span class="h3">Ergots</span><span class="headingEndMark"> — </span>Oral <a class="drug drug_general" data-topicid="9416" href="/d/drug information/9416.html" rel="external">ergotamine</a> has been used as a treatment for cluster headache attacks since the 1940s [<a href="#rid34">34</a>]. Based upon clinical experience, oral ergotamine may be effective if started very early in the attack [<a href="#rid6">6</a>], but modern trials are lacking [<a href="#rid35">35</a>]. Ergotamine is available as a 2 mg sublingual tablet. The initial dose is 2 mg and may be repeated every 30 minutes with a maximum dose of 6 mg daily and 10 mg a week.</p><p>In a small clinical trial, intranasal <a class="drug drug_general" data-topicid="9363" href="/d/drug information/9363.html" rel="external">dihydroergotamine</a> (DHE; 1 mg) was no better than placebo for reducing the duration of cluster headache attacks [<a href="#rid36">36</a>]. However, several small retrospective studies reported that intravenous DHE given in the inpatient or outpatient setting may be effective for cluster headache [<a href="#rid37">37-39</a>]. DHE is given as a 1 mg intravenous bolus and may be repeated at one hour, with a maximum dose of 3 mg in 24 hours. The general limit per week is 6 mg, although this dose is sometimes exceeded in inpatients receiving a repetitive intravenous DHE protocol [<a href="#rid38">38,39</a>]. Because nausea is a common side effect, DHE is typically administered with an antiemetic medication (eg, <a class="drug drug_general" data-topicid="9642" href="/d/drug information/9642.html" rel="external">metoclopramide</a>, <a class="drug drug_general" data-topicid="9820" href="/d/drug information/9820.html" rel="external">promethazine</a>, <a class="drug drug_general" data-topicid="9252" href="/d/drug information/9252.html" rel="external">chlorpromazine</a>, or <a class="drug drug_general" data-topicid="8777" href="/d/drug information/8777.html" rel="external">domperidone</a>) [<a href="#rid40">40,41</a>].</p><p>Ergots are contraindicated during pregnancy because of the potential to induce hypertonic uterine contractions and vasospasm/vasoconstriction, which could cause adverse fetal effects. <a class="drug drug_general" data-topicid="9416" href="/d/drug information/9416.html" rel="external">Ergotamine</a> and DHE should not be given to patients who have received a triptan within the preceding 24 hours due to risk of arterial vasospasm.</p><p class="headingAnchor" id="H3127115877"><span class="h3">Octreotide</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9714" href="/d/drug information/9714.html" rel="external">Octreotide</a> may be effective in the treatment of acute cluster headaches. In a randomized controlled trial of 57 patients, a single dose of subcutaneous octreotide (100 mcg) was superior to placebo in cluster headache response at 30 minutes (52 versus 36 percent, respectively) [<a href="#rid42">42</a>]. Minor gastrointestinal upset was the most common side effect of octreotide treatment.</p><p>Although there has been no direct comparison of <a class="drug drug_general" data-topicid="9714" href="/d/drug information/9714.html" rel="external">octreotide</a> with triptans, the results of this study suggest that octreotide is inferior to both subcutaneous <a class="drug drug_general" data-topicid="9968" href="/d/drug information/9968.html" rel="external">sumatriptan</a> 6 mg [<a href="#rid19">19</a>] and intranasal sumatriptan 20 mg [<a href="#rid22">22</a>] in terms of response rate and time to initial relief.</p><p class="headingAnchor" id="H998704248"><span class="h1">PREVENTIVE INTERVENTIONS</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="10043" href="/d/drug information/10043.html" rel="external">Verapamil</a> is the agent of choice for the initial preventive therapy for most patients with cluster headache. Glucocorticoids are often used adjunctively to provide more rapid benefit during the initial titration of verapamil. In addition, glucocorticoids may be used alone as preventive therapy when cluster attacks are infrequent and short  (<a class="graphic graphic_algorithm graphicRef140577" href="/d/graphic/140577.html" rel="external">algorithm 2</a>). (See <a class="local">'Verapamil plus glucocorticoids for patients with frequent attacks'</a> below and <a class="local">'Glucocorticoids for patients with infrequent attacks'</a> below.)</p><p>Other agents that may be effective include <a class="drug drug_general" data-topicid="119169" href="/d/drug information/119169.html" rel="external">galcanezumab</a>, <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a>, and <a class="drug drug_general" data-topicid="10006" href="/d/drug information/10006.html" rel="external">topiramate</a>. (See <a class="local">'Alternative preventive therapies'</a> below.)</p><p class="headingAnchor" id="H12"><span class="h2">Verapamil plus glucocorticoids for patients with frequent attacks</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="10043" href="/d/drug information/10043.html" rel="external">Verapamil</a> is the drug of choice for prophylaxis of episodic and chronic cluster headache [<a href="#rid3">3,43</a>]. Verapamil may be given alone or with a short course of glucocorticoids to help provide rapid suppression cluster headache attacks during the initial titration. </p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="10043" href="/d/drug information/10043.html" rel="external">Verapamil</a><strong> dosing </strong>– We suggest starting verapamil at 80 mg three times daily for initial dosing and increasing the total daily dose by 120 mg every 14 days as tolerated. Both the regular- and sustained-release formulations are useful, but no direct comparative studies are available. Patients treated with regular-release verapamil should receive the total dose in three divided doses a day, while those treated with the sustained-release formulation should receive two divided doses a day. </p><p></p><p class="bulletIndent1">Most patients respond to a total daily dose of 240 to 480 mg. However, clinical experience suggests that some patients require a total daily dose of up to 960 mg to obtain full prophylactic benefit [<a href="#rid1">1,44</a>]. In an early open-label trial, titration up to a total daily <a class="drug drug_general" data-topicid="10043" href="/d/drug information/10043.html" rel="external">verapamil</a> dose of 1200 mg was employed [<a href="#rid45">45</a>]. Thus, an adequate verapamil trial for most patients entails use of a total daily dose of 480 to 960 mg before the medication is regarded as a failure. The benefit of verapamil is usually seen within two to three weeks. When the bout is ended, verapamil must not be ended abruptly but should be gradually reduced over two to four weeks depending on the dose and finally stopped.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Glucocorticoid coadministration </strong>– For most patients with cluster headaches who tolerate glucocorticoids, we typically give a short course of oral <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> during the initial titration of <a class="drug drug_general" data-topicid="10043" href="/d/drug information/10043.html" rel="external">verapamil</a>. There are no data favoring one regimen of glucocorticoid administration over another. Our preferred regimen is prednisone 100 mg once a day for three days and then tapering by decreasing the dose 10 mg every third day. The dose and tapering regimen may be individualized according to cluster episode patterns, when known. The efficacy for adjunctive glucocorticoids was reported in a short-term treatment trial where patients started verapamil at 40 mg three times daily and increased every three days up to a total daily dose of 360 mg [<a href="#rid46">46</a>]. Those additionally assigned to daily prednisone 100 mg for five days and tapering by 20 mg every three days had fewer cluster attacks in the first week than those assigned to placebo (difference -2.4 attacks; 95% CI -4.8 to -0.03). Adverse effects were mild and similar in both groups.</p><p></p><p>The use of high-dose <a class="drug drug_general" data-topicid="10043" href="/d/drug information/10043.html" rel="external">verapamil</a> is associated with an increased incidence of electrocardiographic (ECG) abnormalities, including heart block and bradycardia [<a href="#rid47">47,48</a>]. Therefore, an ECG should be obtained after each dose increment above a total daily dose of 480 mg. Some experts recommend getting a pretreatment ECG to screen for baseline cardiac arrhythmia [<a href="#rid49">49</a>].</p><p>Other side effects of <a class="drug drug_general" data-topicid="10043" href="/d/drug information/10043.html" rel="external">verapamil</a> include edema, gastrointestinal discomfort, constipation, dull headache, and gingival hyperplasia. However, verapamil is usually well tolerated and can be used safely in conjunction with <a class="drug drug_general" data-topicid="9968" href="/d/drug information/9968.html" rel="external">sumatriptan</a>, <a class="drug drug_general" data-topicid="9416" href="/d/drug information/9416.html" rel="external">ergotamine</a>, glucocorticoids, and other preventive agents.</p><p>The efficacy of <a class="drug drug_general" data-topicid="10043" href="/d/drug information/10043.html" rel="external">verapamil</a> for prevention in cluster headache comes from observational experience and some trial data [<a href="#rid3">3,45,50,51</a>]. In one trial of 30 patients, daily verapamil at 360 mg in three divided doses reduced cluster headache attack frequency and analgesic consumption [<a href="#rid43">43</a>]. During the first week of treatment, the median number of daily attacks, the primary outcome measure, was similar for patients treated with verapamil and placebo (1.1 versus 1.7). However, in the second week, the median number of daily attacks was significantly lower for patients treated with verapamil (0.6 versus 1.7). Additionally, only those assigned to verapamil reported a reduction in headache frequency of &gt;50 percent at two weeks (12 of 15 [80 percent] versus 0 of 15).</p><p class="headingAnchor" id="H14"><span class="h2">Glucocorticoids for patients with infrequent attacks</span><span class="headingEndMark"> — </span>For patients with episodic cluster headache who have active cluster periods that are infrequent and last less than four weeks, we suggest initial preventive therapy with glucocorticoids alone. Glucocorticoids can rapidly suppress cluster attacks during the time required for the longer-acting preventive agents to take effect.</p><p>Glucocorticoids have not been evaluated by rigorous randomized controlled trials for the treatment of cluster headache. However, in several open-label studies and case series, approximately 70 to 80 percent of patients with cluster headache responded to glucocorticoid therapy [<a href="#rid52">52,53</a>]. These studies used different regimens, such as <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> 30 mg daily and higher or <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a> 8 mg daily given in two divided doses. In addition, clinical experience suggests that glucocorticoids are beneficial for reducing the frequency of cluster headache [<a href="#rid1">1</a>].</p><p>There are no data favoring one regimen of glucocorticoid administration over another [<a href="#rid54">54</a>]. We suggest using oral <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> 100 mg once a day for at least three days and then tapering by decreasing the dose 10 mg every third day. Intravenous and oral administration of glucocorticoids can be successfully combined [<a href="#rid55">55</a>].</p><p>Some patients do not respond to other preventive treatments and are attack-free only with glucocorticoids. Consequently, such patients require continuous glucocorticoid therapy, which is problematic due to the deleterious side effects of prolonged systemic glucocorticoid use. These commonly include weight gain, Cushingoid facies, easy bruising and skin fragility, cataracts, aseptic necrosis of the femoral or humeral heads, hypertension, diabetes, infection, and osteoporosis. (See  <a class="medical medical_review" href="/d/html/7988.html" rel="external">"Major adverse effects of systemic glucocorticoids"</a>.)</p><p class="headingAnchor" id="H3664801706"><span class="h2">Alternative preventive therapies</span><span class="headingEndMark"> — </span>For patients who do not respond to or tolerate initial therapy with <a class="drug drug_general" data-topicid="10043" href="/d/drug information/10043.html" rel="external">verapamil</a> and/or glucocorticoids, we use an alternative therapy, using patient risk factors and comorbid conditions to help select among available options. Combination therapy by adding an alternative agent may be beneficial for patients who report partial response to initial therapy. Several classes of medications and some interventional options have shown benefit for patients with cluster headache.</p><p class="headingAnchor" id="H693034098"><span class="h3">Galcanezumab</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="119169" href="/d/drug information/119169.html" rel="external">Galcanezumab</a>, a human monoclonal antibody that binds to the calcitonin gene-related peptide (CGRP) ligand, is modestly effective for the prevention of episodic cluster headache, as demonstrated in a randomized controlled trial that randomly assigned 106 patients with episodic cluster headache in a 1:1 ratio to subcutaneous galcanezumab 300 mg or placebo once a month for two months [<a href="#rid56">56</a>]. At three weeks, the mean number of cluster headaches per week for the galcanezumab and placebo groups decreased by 8.7 and 5.2 (absolute difference 3.5), respectively, from a baseline of approximately 17.5 for both groups. However, effectiveness of galcanezumab assessed at 12 weeks in a subsequent trial was not confirmed for the prevention of chronic cluster headache [<a href="#rid57">57</a>].</p><p>Although its role in cluster headache preventive treatment is not yet defined, <a class="drug drug_general" data-topicid="119169" href="/d/drug information/119169.html" rel="external">galcanezumab</a> is most likely to be reserved for patients with prior episodic cluster headache periods lasting longer than one month when first-line preventative medications are ineffective, poorly tolerated, or contraindicated. It may be less useful for patients with refractory chronic cluster headache.</p><p>The dose of <a class="drug drug_general" data-topicid="119169" href="/d/drug information/119169.html" rel="external">galcanezumab</a> for episodic cluster headache is 300 mg (given as three consecutive doses of 100 mg each) at the onset of the cluster period and then monthly until the end of the cluster period. The drug is administered subcutaneously in the thigh, back of the upper arm, or buttocks. Injection site reactions were the most common adverse events in clinical trials.</p><p class="headingAnchor" id="H16"><span class="h3">Lithium</span><span class="headingEndMark"> — </span>As with glucocorticoids, <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a> (lithium carbonate) has not been evaluated by rigorous randomized controlled trials for the treatment of cluster headache. Evidence of effectiveness is limited:</p><p class="bulletIndent1"><span class="glyph">●</span>In a double-blind controlled trial of less than 30 patients, substantial improvement in episodic cluster headache at one week occurred more often with slow-release <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a> carbonate (800 mg daily) than with placebo (8 of 13 patients [62 percent] versus 6 of 14 [43 percent]), but the difference was statistically nonsignificant [<a href="#rid58">58</a>]. A number of methodologic issues limit the strength of this study, including small patient numbers, very short-term outcome assessment at one week, and early study termination.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A comparative, double-blind crossover trial found that <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a> and <a class="drug drug_general" data-topicid="10043" href="/d/drug information/10043.html" rel="external">verapamil</a> showed similar effectiveness for cluster headache prevention [<a href="#rid51">51</a>]. However, verapamil was associated with more rapid improvement and better tolerability.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a review of older open-label studies, the response rate with <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a> (600 to 1500 mg daily) was as high as 78 percent overall for cluster headache, and 63 percent for episodic cluster headache [<a href="#rid59">59</a>].</p><p></p><p>Because <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a> has a narrow therapeutic window, it is generally used for patients with chronic cluster headache only when other drugs are ineffective or contraindicated.</p><p>The initial dose of <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a> for adults is usually 300 mg once daily, with dose increases every four to five days based upon lithium levels; the typical maintenance dose is 900 to 1200 mg/day given in two to four divided doses of the regular formulation; the sustained-release formulation can be given in two divided doses or once daily. The lithium plasma level should be monitored and should not exceed 1.2 mEq/L (1.2 mmol/L); most patients respond to levels from 0.6 to 0.8 mEq/L (0.6 to 0.8 mmol/L) [<a href="#rid60">60</a>].</p><p>Major side effects of <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a> are hypothyroidism, tremor, and renal dysfunction. In addition, lithium rarely can cause cardiac arrhythmias. Therefore, it is reasonable to obtain an ECG with rhythm strip at baseline for those age &gt;40 years or any age with cardiovascular risk factors, repeating as indicated. Regular monitoring of serum lithium concentration, as well as liver, renal, and thyroid function, is required.</p><p class="headingAnchor" id="H19"><span class="h3">Topiramate</span><span class="headingEndMark"> — </span>In the author's clinical experience, <a class="drug drug_general" data-topicid="10006" href="/d/drug information/10006.html" rel="external">topiramate</a> is an effective add-on medication for cluster headache prevention, most often in combination with <a class="drug drug_general" data-topicid="10043" href="/d/drug information/10043.html" rel="external">verapamil</a>. This strategy can sometimes be used to avoid the need for high-dose verapamil monotherapy or long-term glucocorticoid treatment. However, data from available open-label studies are limited and conflicting regarding the effectiveness of topiramate for the prophylaxis of cluster headache [<a href="#rid61">61-63</a>].</p><p>The recommended starting dose of <a class="drug drug_general" data-topicid="10006" href="/d/drug information/10006.html" rel="external">topiramate</a> is 25 mg/day. It is titrated at weekly intervals in 25 mg increments according to clinical response and tolerance, up to the recommended total daily dose of 100 mg/day given in two divided doses. The main side effects are cognitive disturbances, paresthesia, and weight loss. It is contraindicated in nephrolithiasis. Topiramate is associated with an increased risk of fetal malformations and is contraindicated during pregnancy.</p><p class="headingAnchor" id="H3306952680"><span class="h3">Greater occipital nerve blocks</span><span class="headingEndMark"> — </span>In some cases, greater occipital nerve anesthetic blockade or local glucocorticoid injection are effective, at least temporarily, for patients with refractory chronic cluster headache [<a href="#rid64">64-68</a>]. In a systemic review of clinical trials and observational studies that included 595 patients with cluster headache treated with greater occipital nerve blocks, the response rates ranged from 47 to 100 percent [<a href="#rid69">69</a>]. Onset of response varied from several hours to days, and duration of effect persisted for days to months in some patients. Common adverse effects included injection site pain, head/neck pain, and lightheadedness. Serious adverse effects were uncommon and included alopecia at the injection site, and avascular hip necrosis. These data are limited by small numbers in each study, variable definitions and duration of response, and different agents and doses used for treatment. </p><p class="headingAnchor" id="H20"><span class="h3">Other medications</span><span class="headingEndMark"> — </span>The following medications may have some usefulness as alternative options for patients with medically refractory cluster headache:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pizotifen</strong> – The antiserotonergic drug <a class="drug drug_general" data-topicid="10091" href="/d/drug information/10091.html" rel="external">pizotifen</a> (3 mg daily) was associated with improvement in cluster headache in a single-blind, placebo-controlled, nonrandomized crossover trial of 28 subjects [<a href="#rid35">35,70</a>]. However, a review of seven small studies suggested that pizotifen has only a modest effect [<a href="#rid71">71</a>]. Its use is further limited by side effects such as tiredness and weight gain.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Valproate</strong> – Evidence regarding the utility of valproate (<a class="drug drug_general" data-topicid="10035" href="/d/drug information/10035.html" rel="external">valproic acid</a>) in cluster headache prophylaxis is limited and conflicting. Open-label and retrospective studies suggested benefit [<a href="#rid72">72,73</a>]. In contrast, a two-week double-blind randomized controlled trial involving 96 patients with cluster headache found no statistically significant difference between treatment with valproate (1000 to 2000 mg daily) and placebo [<a href="#rid74">74</a>]. Valproate can be used in a dose between 5 and 20 mg/kg daily.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Capsaicin</strong> – Repeated ipsilateral intranasal application of <a class="drug drug_general" data-topicid="8840" href="/d/drug information/8840.html" rel="external">capsaicin</a> was reported to be effective in approximately two-thirds of patients with cluster headache in two open-label studies [<a href="#rid75">75,76</a>] and one double-blind, placebo-controlled trial [<a href="#rid77">77</a>]. Since capsaicin can induce pain, sneezing, and nasal secretions upon mucosal application, it is uncertain whether most patients were truly blind to treatment assignment.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Triptans</strong> – Limited data from small uncontrolled studies and case reports suggest that two longer-acting triptans (oral <a class="drug drug_general" data-topicid="10167" href="/d/drug information/10167.html" rel="external">naratriptan</a> [<a href="#rid78">78-80</a>] and <a class="drug drug_general" data-topicid="8693" href="/d/drug information/8693.html" rel="external">frovatriptan</a> [<a href="#rid81">81</a>]) are beneficial for cluster headache prevention. While <a class="drug drug_general" data-topicid="9968" href="/d/drug information/9968.html" rel="external">sumatriptan</a> is effective for treating acute cluster headache (see <a class="local">'Triptans'</a> above), a multicenter placebo-controlled trial of 169 patients found that oral sumatriptan was <strong>not</strong> effective for preventing cluster headache attacks [<a href="#rid82">82</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ergotamine</strong> – Some experts advocate the combination drug <a class="drug drug_general" data-topicid="9213" href="/d/drug information/9213.html" rel="external">caffeine</a> (250 mg) and <a class="drug drug_general" data-topicid="9416" href="/d/drug information/9416.html" rel="external">ergotamine</a> (2 mg) given as a rectal suppository to prevent cluster headache attacks during the night [<a href="#rid2">2</a>]. Ergotamine alone is not available as a suppository.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Melatonin</strong> – Oral melatonin (10 mg) was more effective than placebo in a double-blind, randomized controlled study involving 20 patients, but the response rate was relatively low (5 of 10 patients) [<a href="#rid83">83</a>]. In contrast, a crossover study involving nine patients with refractory cluster headache found that adjunctive melatonin did not produce any benefit compared with placebo [<a href="#rid84">84</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Indomethacin</strong> – Although short-term <a class="drug drug_general" data-topicid="8559" href="/d/drug information/8559.html" rel="external">indomethacin</a> treatment is considered ineffective for cluster headache [<a href="#rid85">85</a>], there are reports of occasional patients meeting diagnostic criteria for cluster headache who have responded to indomethacin when used for several weeks at higher doses (≥225 mg daily) [<a href="#rid86">86</a>].</p><p></p><p>The available data suggest no utility for the following agents:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Botulinum toxin</strong> – There is no good evidence that botulinum toxin injections have any prophylactic benefit in the treatment of cluster headache [<a href="#rid87">87</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hyperbaric oxygen</strong> – A small placebo-controlled, double-blind trial found that hyperbaric oxygen was ineffective in preventing cluster headache attacks [<a href="#rid88">88</a>].</p><p></p><p class="headingAnchor" id="H22"><span class="h1">SURGERY AND NEUROSTIMULATION</span><span class="headingEndMark"> — </span>There are several promising but unproven methods using neurostimulation to treat medically refractory cluster headache, including sphenopalatine ganglion stimulation, occipital nerve stimulation, noninvasive vagus nerve stimulation, and deep brain stimulation. All are investigational and require further study to confirm long-term benefit and safety.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Noninvasive vagus nerve stimulation</strong> (VNS) may reduce the frequency of cluster headache attacks, but evidence is inconsistent. In an open-label trial of 97 patients with chronic cluster headache, patients assigned to VNS had statistically significant reductions in the number of attacks per week compared with those assigned to medical treatment [<a href="#rid89">89</a>]. However, a double-blind, randomized trial of 92 subjects with episodic or chronic cluster headache found no difference between noninvasive VNS and sham stimulation in the proportion of treated attacks achieving pain-free status within 15 minutes of treatment initiation [<a href="#rid90">90</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Deep brain stimulation</strong> (DBS) of the posterior inferior hypothalamic region is a promising but unproven investigational treatment for intractable cluster headache [<a href="#rid91">91-95</a>]. Only small numbers of patients have been studied. In an analysis of individual patient data of 40 patients from prior reports, DBS was associated with an overall 77 percent mean reduction of headache frequency among the 75 percent of responders [<a href="#rid96">96</a>]. However, given the investigational status of DBS and the potential for rare but life-threatening adverse effects such as intracerebral hemorrhage [<a href="#rid97">97</a>], stringent criteria for patient selection have been proposed [<a href="#rid98">98</a>]. These require strictly diagnosed, unilateral, chronic cluster headache present daily for at least 24 months and refractory to all state-of-the-art drugs alone and in combination.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Sphenopalatine ganglion stimulation</strong> is performed by surgically implanting a neurostimulator that can be activated by the patient using a handheld remote controller [<a href="#rid99">99</a>]. In a trial of 32 patients with cluster headache, sphenopalatine ganglion stimulation was superior to sham stimulation for pain relief at 15 minutes (67 versus 7 percent) and for several secondary endpoints, including reduction in attack frequency [<a href="#rid100">100</a>]. Serious adverse events involved neurostimulator lead misplacement in three patients and neurostimulator lead migration in two. An open-label follow-up found that effectiveness was maintained for up to 24 months in a majority of responders [<a href="#rid101">101</a>]. Other open-label studies also suggest that sphenopalatine ganglion stimulation is beneficial for a subset of patients with cluster headache [<a href="#rid102">102,103</a>]. The medical device company that previously marketed a sphenopalatine ganglion neurostimulator announced insolvency in 2019 and the device is no longer available.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Occipital nerve stimulation</strong> (ONS) is a technique using electronic stimulation of subcutaneous electrodes implanted in the bilateral occipital region via an implanted pulse generator. Small observational studies have reported benefit for some patients with cluster headache [<a href="#rid104">104-106</a>]. Efficacy in observational studies varies from 36 to 90 percent according to specific outcome measures, surgical approaches, and electrode placement [<a href="#rid107">107</a>]. In a study of 131 patients with medically refractory chronic cluster headache, ONS was associated with an improvement in frequency and severity of cluster attacks [<a href="#rid108">108</a>]. At 24 weeks, 45 percent of patients reported at least a 50 percent reduction in attack frequency. However, infection and lead migration may limit the effectiveness of this therapy. Adverse events included localized pain, neck stiffness, lead migration, and electrode damage. Additional data are needed to help guide patient selection, to optimize the stimulation protocol, and to establish long-term safety of device implantation.</p><p></p><p>Historically, a number of destructive surgical procedures have been used to treat chronic cluster headache [<a href="#rid109">109-111</a>]. Procedures aimed at the sensory trigeminal nerve have targeted the trigeminal ganglion, supraorbital nerve, infraorbital nerve, and trigeminal root. Newer procedures have targeted the occipital nerves. Procedures directed at autonomic pathways have targeted the greater superficial petrosal nerve, nervus intermedius, and sphenopalatine ganglion.</p><p>Surgical methods included radiofrequency thermocoagulation, glycerol ganglio-rhizolysis, alcohol injection, cocaine injection, gamma knife radiosurgery, and nerve sectioning. However, these treatments should be considered only with great caution because reliable long-term observational data are scarce and because complications have included trigeminal neuralgia, anesthesia dolorosa, hypesthesia, meningitis, and cerebrospinal fluid leak [<a href="#rid112">112,113</a>].</p><p>The available evidence, while conflicting, illustrates that trigeminal denervation may <strong>not</strong> be effective in preventing the headache attacks or autonomic symptoms of chronic cluster headache.</p><p class="bulletIndent1"><span class="glyph">●</span>In a prospective study of 10 patients utilizing gamma knife treatment, outcomes graded as excellent, good, or failure were observed in 3, 3, and 4 patients, respectively [<a href="#rid114">114</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a retrospective case series of 17 patients with intractable chronic cluster headache treated with total or partial section of the trigeminal nerve root, complete or near-complete relief of symptoms at a mean follow-up of nearly seven years was reported in 15 patients (88 percent) [<a href="#rid112">112</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a case report, complete surgical section of the trigeminal sensory root had no long-term effect on the frequency or intensity of cluster attacks [<a href="#rid115">115</a>].</p><p></p><p class="headingAnchor" id="H48341120"><span class="h1">MORBIDITY AND PROGNOSIS</span><span class="headingEndMark"> — </span>Cluster headache is the most prominent of the trigeminal autonomic cephalalgias. It is recognized as so vicious that some patients attempt suicide if the disease is not diagnosed or successfully treated [<a href="#rid5">5</a>]. Cluster headache has been associated with a reduced quality of life and an increased risk of depression [<a href="#rid116">116,117</a>]. </p><p>Limited data suggest that cluster headache is a lifelong condition, although the proportion of patients experiencing cluster headache attacks gradually declines with increasing age [<a href="#rid35">35,118,119</a>]. Nevertheless, even 15 years after cluster headache onset, attacks still occur in 80 percent of patients [<a href="#rid118">118</a>]. Cluster headache also results in marked functional disability, even when appropriate treatments are used [<a href="#rid120">120,121</a>].</p><p class="headingAnchor" id="H3228252784"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/110285.html" rel="external">"Society guideline links: Migraine and other primary headache disorders"</a>.)</p><p class="headingAnchor" id="H27"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or email these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topic (see  <a class="medical medical_patient" href="/d/html/720.html" rel="external">"Patient education: Headache treatment in adults (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H28"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Acute treatment</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Initial therapy</strong> – For patients with acute cluster headache, we suggest initial treatment with oxygen  (<a class="graphic graphic_algorithm graphicRef140576" href="/d/graphic/140576.html" rel="external">algorithm 1</a>) (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). Triptans (such as subcutaneous <a class="drug drug_general" data-topicid="9968" href="/d/drug information/9968.html" rel="external">sumatriptan</a> 6 mg) are a reasonable alternative when oxygen is not effective or readily available and may be more convenient for some patients. However, triptans are contraindicated in some patients (eg, those with ischemic cardiovascular disease or stroke, or uncontrolled arterial hypertension)  (<a class="graphic graphic_table graphicRef141582" href="/d/graphic/141582.html" rel="external">table 2</a>). (See <a class="local">'Acute headache treatment'</a> above and <a class="local">'Oxygen'</a> above and <a class="local">'Triptans'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Alternative therapies</strong> – For patients with acute cluster headache who do not respond to or tolerate initial therapy with oxygen and/or triptans, alternatives include intranasal <a class="drug drug_general" data-topicid="9558" href="/d/drug information/9558.html" rel="external">lidocaine</a>, oral <a class="drug drug_general" data-topicid="9416" href="/d/drug information/9416.html" rel="external">ergotamine</a>, and intravenous <a class="drug drug_general" data-topicid="9363" href="/d/drug information/9363.html" rel="external">dihydroergotamine</a>. These agents are associated with potential toxicity and/or have less evidence of efficacy than initial treatment options. (See <a class="local">'Lidocaine'</a> above and <a class="local">'Ergots'</a> above.)</p><p></p><p class="bulletIndent2">Preventive therapy should be started without delay once a cluster episode begins with the goal of suppressing attacks over the expected duration of the cluster period  (<a class="graphic graphic_algorithm graphicRef140577" href="/d/graphic/140577.html" rel="external">algorithm 2</a>). (See <a class="local">'Headache prevention'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Preventive treatment</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Patients with frequent and/or longer cluster periods</strong> – For patients with chronic cluster headache (ie, continuous headaches or remission intervals of &lt;3 months) and those with episodic cluster headache with relatively long-lasting active periods (ie, four weeks or longer), we use combination therapy. Our approach is as follows (see <a class="local">'Verapamil plus glucocorticoids for patients with frequent attacks'</a> above):</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>We suggest preventive therapy with <a class="drug drug_general" data-topicid="10043" href="/d/drug information/10043.html" rel="external">verapamil</a> rather than other agents (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). Verapamil is generally well tolerated and effective in this setting. The starting dose is usually 240 mg daily in three divided doses. Most patients respond to a total dose of 240 to 480 mg daily. Titration to a total dose of up to 960 mg daily may be necessary for some patients to obtain full prophylactic benefit.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>We also suggest a short course of glucocorticoids to provide rapid benefit during the initial titration of <a class="drug drug_general" data-topicid="10043" href="/d/drug information/10043.html" rel="external">verapamil</a> (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). We use oral <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> 100 mg once a day for at least three days and then tapering by decreasing the dose 10 mg every third day. Patients who experience good relief with symptomatic treatment and those with relative contraindications to glucocorticoids may choose to forego such treatment. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Patients with infrequent and shorter cluster periods</strong> – For patients with episodic cluster headache who have active cluster periods that are infrequent and last less than four weeks, we suggest initial preventive therapy with glucocorticoids alone (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). We prefer oral <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> 100 mg once a day for at least three days, followed by a taper with a dose reduction of 10 mg every three days. (See <a class="local">'Glucocorticoids for patients with infrequent attacks'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Alternative options </strong>– We reserve <a class="drug drug_general" data-topicid="119169" href="/d/drug information/119169.html" rel="external">galcanezumab</a> for patients with prior cluster headache periods lasting longer than one month when first-line preventive medications are ineffective, poorly tolerated, or contraindicated. (See <a class="local">'Galcanezumab'</a> above.)</p><p></p><p class="bulletIndent2">Alternative medications such as <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a>, <a class="drug drug_general" data-topicid="10006" href="/d/drug information/10006.html" rel="external">topiramate</a>, and interventional procedures may be useful for some patients who do not respond to initial preventive therapies. (See <a class="local">'Lithium'</a> above and <a class="local">'Topiramate'</a> above and <a class="local">'Greater occipital nerve blocks'</a> above and <a class="local">'Other medications'</a> above.)</p><p></p><p class="bulletIndent2">Neurostimulation and other surgical options used to treat medically refractory cluster headache are investigational and require further study to confirm long-term benefit and safety. Destructive surgical procedures aimed at the sensory trigeminal nerve or autonomic pathways are unproven and should be viewed with great caution. (See <a class="local">'Surgery and neurostimulation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prognosis</strong> – Limited data suggest that cluster headache is a lifelong condition, but attacks gradually decline with increasing age. Cluster headache results in severe functional consequences even when appropriately treated. (See <a class="local">'Morbidity and prognosis'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Obermann M, Holle D, Naegel S, et al. Pharmacotherapy options for cluster headache. Expert Opin Pharmacother 2015; 16:1177.</a></li><li><a class="nounderline abstract_t">Dodick DW, Rozen TD, Goadsby PJ, Silberstein SD. Cluster headache. Cephalalgia 2000; 20:787.</a></li><li><a class="nounderline abstract_t">May A. Headaches with (ipsilateral) autonomic symptoms. J Neurol 2003; 250:1273.</a></li><li><a class="nounderline abstract_t">Nilsson Remahl AI, Laudon Meyer E, Cordonnier C, Goadsby PJ. Placebo response in cluster headache trials: a review. Cephalalgia 2003; 23:504.</a></li><li><a class="nounderline abstract_t">May A. Cluster headache: pathogenesis, diagnosis, and management. Lancet 2005; 366:843.</a></li><li><a class="nounderline abstract_t">May A, Leone M, Afra J, et al. EFNS guidelines on the treatment of cluster headache and other trigeminal-autonomic cephalalgias. Eur J Neurol 2006; 13:1066.</a></li><li><a class="nounderline abstract_t">Francis GJ, Becker WJ, Pringsheim TM. Acute and preventive pharmacologic treatment of cluster headache. Neurology 2010; 75:463.</a></li><li><a class="nounderline abstract_t">Petersen AS, Barloese MC, Jensen RH. Oxygen treatment of cluster headache: a review. Cephalalgia 2014; 34:1079.</a></li><li><a class="nounderline abstract_t">Evers S, Rapoport A, International Headache Society. The use of oxygen in cluster headache treatment worldwide - a survey of the International Headache Society (IHS). Cephalalgia 2017; 37:396.</a></li><li><a class="nounderline abstract_t">Cohen AS, Burns B, Goadsby PJ. High-flow oxygen for treatment of cluster headache: a randomized trial. JAMA 2009; 302:2451.</a></li><li><a class="nounderline abstract_t">Kudrow L. Response of cluster headache attacks to oxygen inhalation. Headache 1981; 21:1.</a></li><li><a class="nounderline abstract_t">Fogan L. Treatment of cluster headache. A double-blind comparison of oxygen v air inhalation. Arch Neurol 1985; 42:362.</a></li><li><a class="nounderline abstract_t">Bennett MH, French C, Schnabel A, et al. Normobaric and hyperbaric oxygen therapy for the treatment and prevention of migraine and cluster headache. Cochrane Database Syst Rev 2015; :CD005219.</a></li><li><a class="nounderline abstract_t">Singhal AB, Maas MB, Goldstein JN, et al. High-flow oxygen therapy for treatment of acute migraine: A randomized crossover trial. Cephalalgia 2017; 37:730.</a></li><li><a class="nounderline abstract_t">Rozen TD. High oxygen flow rates for cluster headache. Neurology 2004; 63:593.</a></li><li><a class="nounderline abstract_t">Petersen AS, Barloese MC, Lund NL, Jensen RH. Oxygen therapy for cluster headache. A mask comparison trial. A single-blinded, placebo-controlled, crossover study. Cephalalgia 2017; 37:214.</a></li><li><a class="nounderline abstract_t">Di Sabato F, Fusco BM, Pelaia P, Giacovazzo M. Hyperbaric oxygen therapy in cluster headache. Pain 1993; 52:243.</a></li><li><a class="nounderline abstract_t">Law S, Derry S, Moore RA. Triptans for acute cluster headache. Cochrane Database Syst Rev 2013; :CD008042.</a></li><li><a class="nounderline abstract_t">Treatment of acute cluster headache with sumatriptan. The Sumatriptan Cluster Headache Study Group. N Engl J Med 1991; 325:322.</a></li><li><a class="nounderline abstract_t">Ekbom K, Monstad I, Prusinski A, et al. Subcutaneous sumatriptan in the acute treatment of cluster headache: a dose comparison study. The Sumatriptan Cluster Headache Study Group. Acta Neurol Scand 1993; 88:63.</a></li><li><a class="nounderline abstract_t">Ekbom K, Krabbe A, Micieli G, et al. Cluster headache attacks treated for up to three months with subcutaneous sumatriptan (6 mg). Sumatriptan Cluster Headache Long-term Study Group. Cephalalgia 1995; 15:230.</a></li><li><a class="nounderline abstract_t">van Vliet JA, Bahra A, Martin V, et al. Intranasal sumatriptan in cluster headache: randomized placebo-controlled double-blind study. Neurology 2003; 60:630.</a></li><li><a class="nounderline abstract_t">Cittadini E, May A, Straube A, et al. Effectiveness of intranasal zolmitriptan in acute cluster headache: a randomized, placebo-controlled, double-blind crossover study. Arch Neurol 2006; 63:1537.</a></li><li><a class="nounderline abstract_t">Rapoport AM, Mathew NT, Silberstein SD, et al. Zolmitriptan nasal spray in the acute treatment of cluster headache: a double-blind study. Neurology 2007; 69:821.</a></li><li><a class="nounderline abstract_t">Bahra A, Gawel MJ, Hardebo JE, et al. Oral zolmitriptan is effective in the acute treatment of cluster headache. Neurology 2000; 54:1832.</a></li><li><a class="nounderline abstract_t">Paemeleire K, Bahra A, Evers S, et al. Medication-overuse headache in patients with cluster headache. Neurology 2006; 67:109.</a></li><li><a class="nounderline abstract_t">Kallweit U, Sándor PS. Sumatriptan in excessive doses over 15 years in a patient with chronic cluster headache. Headache 2011; 51:1546.</a></li><li><a class="nounderline abstract_t">Centonze V, Polito BM, Attolini E, et al. Use of high sumatriptan dosages during episodic cluster headache: three clinical cases. Headache 1996; 36:389.</a></li><li><a class="nounderline abstract_t">Robbins L. Intranasal lidocaine for cluster headache. Headache 1995; 35:83.</a></li><li><a class="nounderline abstract_t">Morgan A, Jessop V. Best BETs from the Manchester Royal Infirmary. BET 2: should intranasal lidocaine be used in patients with acute cluster headache? Emerg Med J 2013; 30:769.</a></li><li><a class="nounderline abstract_t">Costa A, Pucci E, Antonaci F, et al. The effect of intranasal cocaine and lidocaine on nitroglycerin-induced attacks in cluster headache. Cephalalgia 2000; 20:85.</a></li><li><a class="nounderline abstract_t">Hardebo JE, Elner A. Nerves and vessels in the pterygopalatine fossa and symptoms of cluster headache. Headache 1987; 27:528.</a></li><li><a class="nounderline abstract_t">Kittrelle JP, Grouse DS, Seybold ME. Cluster headache. Local anesthetic abortive agents. Arch Neurol 1985; 42:496.</a></li><li><a class="nounderline abstract_t">Ekbom K. Ergotamine tartrate orally in Horton's histaminic cephalalgia (also called Harris's ciliary neuralgia). Acta Psychiatr Scand 1947; 46:106.</a></li><li><a class="nounderline abstract_t">Matharu M. Cluster headache. BMJ Clin Evid 2010; 2010.</a></li><li><a class="nounderline abstract_t">Andersson PG, Jespersen LT. Dihydroergotamine nasal spray in the treatment of attacks of cluster headache. A double-blind trial versus placebo. Cephalalgia 1986; 6:51.</a></li><li><a class="nounderline abstract_t">Magnoux E, Zlotnik G. Outpatient intravenous dihydroergotamine for refractory cluster headache. Headache 2004; 44:249.</a></li><li><a class="nounderline abstract_t">Mather PJ, Silberstein SD, Schulman EA, Hopkins MM. The treatment of cluster headache with repetitive intravenous dihydroergotamine. Headache 1991; 31:525.</a></li><li><a class="nounderline abstract_t">Nagy AJ, Gandhi S, Bhola R, Goadsby PJ. Intravenous dihydroergotamine for inpatient management of refractory primary headaches. Neurology 2011; 77:1827.</a></li><li><a class="nounderline abstract_t">Robbins NM, Ito H, Scheinman MM, Goadsby PJ. Safety of domperidone in treating nausea associated with dihydroergotamine infusion and headache. Neurology 2016; 87:2522.</a></li><li><a class="nounderline abstract_t">Robbins NM, Goadsby PJ. Author response: Safety of domperidone in treating nausea associated with dihydroergotamine infusion and headache. Neurology 2017; 88:2156.</a></li><li><a class="nounderline abstract_t">Matharu MS, Levy MJ, Meeran K, Goadsby PJ. Subcutaneous octreotide in cluster headache: randomized placebo-controlled double-blind crossover study. Ann Neurol 2004; 56:488.</a></li><li><a class="nounderline abstract_t">Leone M, D'Amico D, Frediani F, et al. Verapamil in the prophylaxis of episodic cluster headache: a double-blind study versus placebo. Neurology 2000; 54:1382.</a></li><li><a class="nounderline abstract_t">Goadsby PJ, Cittadini E, Burns B, Cohen AS. Trigeminal autonomic cephalalgias: diagnostic and therapeutic developments. Curr Opin Neurol 2008; 21:323.</a></li><li><a class="nounderline abstract_t">Gabai IJ, Spierings EL. Prophylactic treatment of cluster headache with verapamil. Headache 1989; 29:167.</a></li><li><a class="nounderline abstract_t">Obermann M, Nägel S, Ose C, et al. Safety and efficacy of prednisone versus placebo in short-term prevention of episodic cluster headache: a multicentre, double-blind, randomised controlled trial. Lancet Neurol 2021; 20:29.</a></li><li><a class="nounderline abstract_t">Cohen AS, Matharu MS, Goadsby PJ. Electrocardiographic abnormalities in patients with cluster headache on verapamil therapy. Neurology 2007; 69:668.</a></li><li><a class="nounderline abstract_t">Lanteri-Minet M, Silhol F, Piano V, Donnet A. Cardiac safety in cluster headache patients using the very high dose of verapamil (≥720 mg/day). J Headache Pain 2011; 12:173.</a></li><li><a class="nounderline abstract_t">Koppen H, Stolwijk J, Wilms EB, et al. Cardiac monitoring of high-dose verapamil in cluster headache: An international Delphi study. Cephalalgia 2016; 36:1385.</a></li><li><a class="nounderline abstract_t">Matharu MS, Boes CJ, Goadsby PJ. Management of trigeminal autonomic cephalgias and hemicrania continua. Drugs 2003; 63:1637.</a></li><li><a class="nounderline abstract_t">Bussone G, Leone M, Peccarisi C, et al. Double blind comparison of lithium and verapamil in cluster headache prophylaxis. Headache 1990; 30:411.</a></li><li><a class="nounderline abstract_t">Ekbom K, Hardebo JE. Cluster headache: aetiology, diagnosis and management. Drugs 2002; 62:61.</a></li><li><a class="nounderline abstract_t">Dodick DW, Capobianco DJ. Treatment and management of cluster headache. Curr Pain Headache Rep 2001; 5:83.</a></li><li><a class="nounderline abstract_t">May A, Evers S, Goadsby PJ, et al. European Academy of Neurology guidelines on the treatment of cluster headache. Eur J Neurol 2023; 30:2955.</a></li><li><a class="nounderline abstract_t">Mir P, Alberca R, Navarro A, et al. Prophylactic treatment of episodic cluster headache with intravenous bolus of methylprednisolone. Neurol Sci 2003; 24:318.</a></li><li><a class="nounderline abstract_t">Goadsby PJ, Dodick DW, Leone M, et al. Trial of Galcanezumab in Prevention of Episodic Cluster Headache. N Engl J Med 2019; 381:132.</a></li><li><a class="nounderline abstract_t">Dodick DW, Goadsby PJ, Lucas C, et al. Phase 3 randomized, placebo-controlled study of galcanezumab in patients with chronic cluster headache: Results from 3-month double-blind treatment. Cephalalgia 2020; 40:935.</a></li><li><a class="nounderline abstract_t">Steiner TJ, Hering R, Couturier EG, et al. Double-blind placebo-controlled trial of lithium in episodic cluster headache. Cephalalgia 1997; 17:673.</a></li><li><a class="nounderline abstract_t">Ekbom K. Lithium for cluster headache: review of the literature and preliminary results of long-term treatment. Headache 1981; 21:132.</a></li><li><a class="nounderline abstract_t">Hoffmann J, May A. Diagnosis, pathophysiology, and management of cluster headache. Lancet Neurol 2018; 17:75.</a></li><li><a class="nounderline abstract_t">Wheeler SD, Carrazana EJ. Topiramate-treated cluster headache. Neurology 1999; 53:234.</a></li><li><a class="nounderline abstract_t">Förderreuther S, Mayer M, Straube A. Treatment of cluster headache with topiramate: effects and side-effects in five patients. Cephalalgia 2002; 22:186.</a></li><li><a class="nounderline abstract_t">Leone M, Dodick D, Rigamonti A, et al. Topiramate in cluster headache prophylaxis: an open trial. Cephalalgia 2003; 23:1001.</a></li><li><a class="nounderline abstract_t">Peres MF, Stiles MA, Siow HC, et al. Greater occipital nerve blockade for cluster headache. Cephalalgia 2002; 22:520.</a></li><li><a class="nounderline abstract_t">Leroux E, Valade D, Taifas I, et al. Suboccipital steroid injections for transitional treatment of patients with more than two cluster headache attacks per day: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 2011; 10:891.</a></li><li><a class="nounderline abstract_t">Ambrosini A, Vandenheede M, Rossi P, et al. Suboccipital injection with a mixture of rapid- and long-acting steroids in cluster headache: a double-blind placebo-controlled study. Pain 2005; 118:92.</a></li><li><a class="nounderline abstract_t">Gantenbein AR, Lutz NJ, Riederer F, Sándor PS. Efficacy and safety of 121 injections of the greater occipital nerve in episodic and chronic cluster headache. Cephalalgia 2012; 32:630.</a></li><li><a class="nounderline abstract_t">Lambru G, Abu Bakar N, Stahlhut L, et al. Greater occipital nerve blocks in chronic cluster headache: a prospective open-label study. Eur J Neurol 2014; 21:338.</a></li><li><a class="nounderline abstract_t">Gordon A, Roe T, Villar-Martínez MD, et al. Effectiveness and safety profile of greater occipital nerve blockade in cluster headache: a systematic review. J Neurol Neurosurg Psychiatry 2023; 95:73.</a></li><li><a class="nounderline abstract_t">Ekbom K. Prophylactic treatment of cluster headache with a new serotonin antagonist, BC 105. Acta Neurol Scand 1969; 45:601.</a></li><li><a class="nounderline abstract_t">Speight TM, Avery GS. Pizotifen (BC-105): a review of its pharmacological properties and its therapeutic efficacy in vascular headaches. Drugs 1972; 3:159.</a></li><li><a class="nounderline abstract_t">Hering R, Kuritzky A. Sodium valproate in the treatment of cluster headache: an open clinical trial. Cephalalgia 1989; 9:195.</a></li><li><a class="nounderline abstract_t">Gallagher RM, Mueller LL, Freitag FG. Divalproex sodium in the treatment of migraine and cluster headaches. J Am Osteopath Assoc 2002; 102:92.</a></li><li><a class="nounderline abstract_t">El Amrani M, Massiou H, Bousser MG. A negative trial of sodium valproate in cluster headache: methodological issues. Cephalalgia 2002; 22:205.</a></li><li><a class="nounderline abstract_t">Sicuteri F, Fusco BM, Marabini S, et al. Beneficial effect of capsaicin application to the nasal mucosa in cluster headache. Clin J Pain 1989; 5:49.</a></li><li><a class="nounderline abstract_t">Fusco BM, Marabini S, Maggi CA, et al. Preventative effect of repeated nasal applications of capsaicin in cluster headache. Pain 1994; 59:321.</a></li><li><a class="nounderline abstract_t">Marks DR, Rapoport A, Padla D, et al. A double-blind placebo-controlled trial of intranasal capsaicin for cluster headache. Cephalalgia 1993; 13:114.</a></li><li><a class="nounderline abstract_t">Eekers PJ, Koehler PJ. Naratriptan prophylactic treatment in cluster headache. Cephalalgia 2001; 21:75.</a></li><li><a class="nounderline abstract_t">Loder E. Naratriptan in the prophylaxis of cluster headache. Headache 2002; 42:56.</a></li><li><a class="nounderline abstract_t">Mulder LJ, Spierings EL. Naratriptan in the preventive treatment of cluster headache. Cephalalgia 2002; 22:815.</a></li><li><a class="nounderline abstract_t">Siow HC, Pozo-Rosich P, Silberstein SD. Frovatriptan for the treatment of cluster headaches. Cephalalgia 2004; 24:1045.</a></li><li><a class="nounderline abstract_t">Monstad I, Krabbe A, Micieli G, et al. Preemptive oral treatment with sumatriptan during a cluster period. Headache 1995; 35:607.</a></li><li><a class="nounderline abstract_t">Leone M, D'Amico D, Moschiano F, et al. Melatonin versus placebo in the prophylaxis of cluster headache: a double-blind pilot study with parallel groups. Cephalalgia 1996; 16:494.</a></li><li><a class="nounderline abstract_t">Pringsheim T, Magnoux E, Dobson CF, et al. Melatonin as adjunctive therapy in the prophylaxis of cluster headache: a pilot study. Headache 2002; 42:787.</a></li><li><a class="nounderline abstract_t">Antonaci F, Costa A, Ghirmai S, et al. Parenteral indomethacin (the INDOTEST) in cluster headache. Cephalalgia 2003; 23:193.</a></li><li><a class="nounderline abstract_t">Prakash S, Shah ND, Chavda BV. Cluster headache responsive to indomethacin: Case reports and a critical review of the literature. Cephalalgia 2010; 30:975.</a></li><li><a class="nounderline abstract_t">Evers S, Rahmann A, Vollmer-Haase J, Husstedt IW. Treatment of headache with botulinum toxin A--a review according to evidence-based medicine criteria. Cephalalgia 2002; 22:699.</a></li><li><a class="nounderline abstract_t">Nilsson Remahl AI, Ansjön R, Lind F, Waldenlind E. Hyperbaric oxygen treatment of active cluster headache: a double-blind placebo-controlled cross-over study. Cephalalgia 2002; 22:730.</a></li><li><a class="nounderline abstract_t">Gaul C, Diener HC, Silver N, et al. Non-invasive vagus nerve stimulation for PREVention and Acute treatment of chronic cluster headache (PREVA): A randomised controlled study. Cephalalgia 2016; 36:534.</a></li><li><a class="nounderline abstract_t">Goadsby PJ, de Coo IF, Silver N, et al. Non-invasive vagus nerve stimulation for the acute treatment of episodic and chronic cluster headache: A randomized, double-blind, sham-controlled ACT2 study. Cephalalgia 2018; 38:959.</a></li><li><a class="nounderline abstract_t">Matharu MS, Zrinzo L. Deep brain stimulation in cluster headache: hypothalamus or midbrain tegmentum? Curr Pain Headache Rep 2010; 14:151.</a></li><li><a class="nounderline abstract_t">Fontaine D, Lanteri-Minet M, Ouchchane L, et al. Anatomical location of effective deep brain stimulation electrodes in chronic cluster headache. Brain 2010; 133:1214.</a></li><li><a class="nounderline abstract_t">Fontaine D, Lazorthes Y, Mertens P, et al. Safety and efficacy of deep brain stimulation in refractory cluster headache: a randomized placebo-controlled double-blind trial followed by a 1-year open extension. J Headache Pain 2010; 11:23.</a></li><li><a class="nounderline abstract_t">Akram H, Miller S, Lagrata S, et al. Ventral tegmental area deep brain stimulation for refractory chronic cluster headache. Neurology 2016; 86:1676.</a></li><li><a class="nounderline abstract_t">Leone M, Franzini A, Broggi G, Bussone G. Hypothalamic stimulation for intractable cluster headache: long-term experience. Neurology 2006; 67:150.</a></li><li><a class="nounderline abstract_t">Nowacki A, Schober M, Nader L, et al. Deep Brain Stimulation for Chronic Cluster Headache: Meta-Analysis of Individual Patient Data. Ann Neurol 2020; 88:956.</a></li><li><a class="nounderline abstract_t">Schoenen J, Di Clemente L, Vandenheede M, et al. Hypothalamic stimulation in chronic cluster headache: a pilot study of efficacy and mode of action. Brain 2005; 128:940.</a></li><li><a class="nounderline abstract_t">Leone M, May A, Franzini A, et al. Deep brain stimulation for intractable chronic cluster headache: proposals for patient selection. Cephalalgia 2004; 24:934.</a></li><li><a class="nounderline abstract_t">Jürgens TP, Schoenen J, Rostgaard J, et al. Stimulation of the sphenopalatine ganglion in intractable cluster headache: expert consensus on patient selection and standards of care. Cephalalgia 2014; 34:1100.</a></li><li><a class="nounderline abstract_t">Schoenen J, Jensen RH, Lantéri-Minet M, et al. Stimulation of the sphenopalatine ganglion (SPG) for cluster headache treatment. Pathway CH-1: a randomized, sham-controlled study. Cephalalgia 2013; 33:816.</a></li><li><a class="nounderline abstract_t">Barloese MC, Jürgens TP, May A, et al. Cluster headache attack remission with sphenopalatine ganglion stimulation: experiences in chronic cluster headache patients through 24 months. J Headache Pain 2016; 17:67.</a></li><li><a class="nounderline abstract_t">Barloese M, Petersen A, Stude P, et al. Sphenopalatine ganglion stimulation for cluster headache, results from a large, open-label European registry. J Headache Pain 2018; 19:6.</a></li><li><a class="nounderline abstract_t">Jürgens TP, Barloese M, May A, et al. Long-term effectiveness of sphenopalatine ganglion stimulation for cluster headache. Cephalalgia 2017; 37:423.</a></li><li><a class="nounderline abstract_t">Burns B, Watkins L, Goadsby PJ. Treatment of intractable chronic cluster headache by occipital nerve stimulation in 14 patients. Neurology 2009; 72:341.</a></li><li><a class="nounderline abstract_t">Magis D, Allena M, Bolla M, et al. Occipital nerve stimulation for drug-resistant chronic cluster headache: a prospective pilot study. Lancet Neurol 2007; 6:314.</a></li><li><a class="nounderline abstract_t">Leplus A, Fontaine D, Donnet A, et al. Long-Term Efficacy of Occipital Nerve Stimulation for Medically Intractable Cluster Headache. Neurosurgery 2021; 88:375.</a></li><li><a class="nounderline abstract_t">Kurt E, Kollenburg L, van Dongen R, et al. The Untold Story of Occipital Nerve Stimulation in Patients With Cluster Headache: Surgical Technique in Relation to Clinical Efficacy. Neuromodulation 2024; 27:22.</a></li><li><a class="nounderline abstract_t">Wilbrink LA, de Coo IF, Doesborg PGG, et al. Safety and efficacy of occipital nerve stimulation for attack prevention in medically intractable chronic cluster headache (ICON): a randomised, double-blind, multicentre, phase 3, electrical dose-controlled trial. Lancet Neurol 2021; 20:515.</a></li><li><a class="nounderline abstract_t">Meyer JS, Binns PM, Ericsson AD, Vulpe M. Sphenopalatine gangionectomy for cluster headache. Arch Otolaryngol 1970; 92:475.</a></li><li><a class="nounderline abstract_t">Rowed DW. Chronic cluster headache managed by nervus intermedius section. Headache 1990; 30:401.</a></li><li><a class="nounderline abstract_t">Rozen TD. Interventional treatment for cluster headache: a review of the options. Curr Pain Headache Rep 2002; 6:57.</a></li><li><a class="nounderline abstract_t">Jarrar RG, Black DF, Dodick DW, Davis DH. Outcome of trigeminal nerve section in the treatment of chronic cluster headache. Neurology 2003; 60:1360.</a></li><li><a class="nounderline abstract_t">Donnet A, Tamura M, Valade D, Régis J. Trigeminal nerve radiosurgical treatment in intractable chronic cluster headache: unexpected high toxicity. Neurosurgery 2006; 59:1252.</a></li><li><a class="nounderline abstract_t">Donnet A, Valade D, Régis J. Gamma knife treatment for refractory cluster headache: prospective open trial. J Neurol Neurosurg Psychiatry 2005; 76:218.</a></li><li><a class="nounderline abstract_t">Matharu MS, Goadsby PJ. Persistence of attacks of cluster headache after trigeminal nerve root section. Brain 2002; 125:976.</a></li><li><a class="nounderline abstract_t">Jensen RM, Lyngberg A, Jensen RH. Burden of cluster headache. Cephalalgia 2007; 27:535.</a></li><li><a class="nounderline abstract_t">Louter MA, Wilbrink LA, Haan J, et al. Cluster headache and depression. Neurology 2016; 87:1899.</a></li><li><a class="nounderline abstract_t">Bahra A, May A, Goadsby PJ. Cluster headache: a prospective clinical study with diagnostic implications. Neurology 2002; 58:354.</a></li><li><a class="nounderline abstract_t">Manzoni GC, Terzano MG, Moretti G, Cocchi M. Clinical observations on 76 cluster headache cases. Eur Neurol 1981; 20:88.</a></li><li><a class="nounderline abstract_t">D'Amico D, Rigamonti A, Solari A, et al. Health-related quality of life in patients with cluster headache during active periods. Cephalalgia 2002; 22:818.</a></li><li><a class="nounderline abstract_t">Donnet A, Lanteri-Minet M, Guegan-Massardier E, et al. Chronic cluster headache: a French clinical descriptive study. J Neurol Neurosurg Psychiatry 2007; 78:1354.</a></li></ol></div><div id="topicVersionRevision">Topic 3351 Version 56.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25911317" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Pharmacotherapy options for cluster headache.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11167909" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Cluster headache.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14648142" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Headaches with (ipsilateral) autonomic symptoms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12950375" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Placebo response in cluster headache trials: a review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16139660" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Cluster headache: pathogenesis, diagnosis, and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16987158" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : EFNS guidelines on the treatment of cluster headache and other trigeminal-autonomic cephalalgias.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20679639" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Acute and preventive pharmacologic treatment of cluster headache.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24723673" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Oxygen treatment of cluster headache: a review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27121359" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : The use of oxygen in cluster headache treatment worldwide - a survey of the International Headache Society (IHS).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19996400" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : High-flow oxygen for treatment of cluster headache: a randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7007285" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Response of cluster headache attacks to oxygen inhalation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3885921" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Treatment of cluster headache. A double-blind comparison of oxygen v air inhalation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26709672" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Normobaric and hyperbaric oxygen therapy for the treatment and prevention of migraine and cluster headache.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27206964" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : High-flow oxygen therapy for treatment of acute migraine: A randomized crossover trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15304611" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : High oxygen flow rates for cluster headache.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27013239" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Oxygen therapy for cluster headache. A mask comparison trial. A single-blinded, placebo-controlled, crossover study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8455970" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Hyperbaric oxygen therapy in cluster headache.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24353996" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Triptans for acute cluster headache.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1647496" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Treatment of acute cluster headache with sumatriptan. The Sumatriptan Cluster Headache Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8396833" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Subcutaneous sumatriptan in the acute treatment of cluster headache: a dose comparison study. The Sumatriptan Cluster Headache Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7553814" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Cluster headache attacks treated for up to three months with subcutaneous sumatriptan (6 mg). Sumatriptan Cluster Headache Long-term Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12601104" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Intranasal sumatriptan in cluster headache: randomized placebo-controlled double-blind study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16966497" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Effectiveness of intranasal zolmitriptan in acute cluster headache: a randomized, placebo-controlled, double-blind crossover study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17724283" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Zolmitriptan nasal spray in the acute treatment of cluster headache: a double-blind study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10802793" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Oral zolmitriptan is effective in the acute treatment of cluster headache.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16832088" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Medication-overuse headache in patients with cluster headache.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22082424" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Sumatriptan in excessive doses over 15 years in a patient with chronic cluster headache.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8707559" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Use of high sumatriptan dosages during episodic cluster headache: three clinical cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7737866" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Intranasal lidocaine for cluster headache.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23943642" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Best BETs from the Manchester Royal Infirmary. BET 2: should intranasal lidocaine be used in patients with acute cluster headache?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10961763" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : The effect of intranasal cocaine and lidocaine on nitroglycerin-induced attacks in cluster headache.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3692815" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Nerves and vessels in the pterygopalatine fossa and symptoms of cluster headache.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3994568" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Cluster headache. Local anesthetic abortive agents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Ergotamine tartrate orally in Horton's histaminic cephalalgia (also called Harris's ciliary neuralgia)</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21718584" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Cluster headache.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3516408" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Dihydroergotamine nasal spray in the treatment of attacks of cluster headache. A double-blind trial versus placebo.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15012663" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Outpatient intravenous dihydroergotamine for refractory cluster headache.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1960057" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : The treatment of cluster headache with repetitive intravenous dihydroergotamine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22049203" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Intravenous dihydroergotamine for inpatient management of refractory primary headaches.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27837002" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Safety of domperidone in treating nausea associated with dihydroergotamine infusion and headache.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28554903" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Author response: Safety of domperidone in treating nausea associated with dihydroergotamine infusion and headache.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15455406" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Subcutaneous octreotide in cluster headache: randomized placebo-controlled double-blind crossover study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10746617" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Verapamil in the prophylaxis of episodic cluster headache: a double-blind study versus placebo.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18451717" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Trigeminal autonomic cephalalgias: diagnostic and therapeutic developments.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2708046" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Prophylactic treatment of cluster headache with verapamil.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33245858" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Safety and efficacy of prednisone versus placebo in short-term prevention of episodic cluster headache: a multicentre, double-blind, randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17698788" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Electrocardiographic abnormalities in patients with cluster headache on verapamil therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21258839" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Cardiac safety in cluster headache patients using the very high dose of verapamil (≥720 mg/day).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26868817" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Cardiac monitoring of high-dose verapamil in cluster headache: An international Delphi study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12904085" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Management of trigeminal autonomic cephalgias and hemicrania continua.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2205598" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Double blind comparison of lithium and verapamil in cluster headache prophylaxis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11790156" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Cluster headache: aetiology, diagnosis and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11252143" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Treatment and management of cluster headache.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37515405" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : European Academy of Neurology guidelines on the treatment of cluster headache.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14716526" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Prophylactic treatment of episodic cluster headache with intravenous bolus of methylprednisolone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31291515" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Trial of Galcanezumab in Prevention of Episodic Cluster Headache.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32050782" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Phase 3 randomized, placebo-controlled study of galcanezumab in patients with chronic cluster headache: Results from 3-month double-blind treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9350389" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Double-blind placebo-controlled trial of lithium in episodic cluster headache.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7021473" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Lithium for cluster headache: review of the literature and preliminary results of long-term treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29174963" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Diagnosis, pathophysiology, and management of cluster headache.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10408573" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Topiramate-treated cluster headache.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12047455" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Treatment of cluster headache with topiramate: effects and side-effects in five patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14984235" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Topiramate in cluster headache prophylaxis: an open trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12230593" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Greater occipital nerve blockade for cluster headache.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21903477" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Suboccipital steroid injections for transitional treatment of patients with more than two cluster headache attacks per day: a randomised, double-blind, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16202532" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Suboccipital injection with a mixture of rapid- and long-acting steroids in cluster headache: a double-blind placebo-controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22623755" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Efficacy and safety of 121 injections of the greater occipital nerve in episodic and chronic cluster headache.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24313966" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Greater occipital nerve blocks in chronic cluster headache: a prospective open-label study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36948579" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Effectiveness and safety profile of greater occipital nerve blockade in cluster headache: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4391566" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Prophylactic treatment of cluster headache with a new serotonin antagonist, BC 105.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4403890" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Pizotifen (BC-105): a review of its pharmacological properties and its therapeutic efficacy in vascular headaches.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2507161" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Sodium valproate in the treatment of cluster headache: an open clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11866398" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Divalproex sodium in the treatment of migraine and cluster headaches.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12047460" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : A negative trial of sodium valproate in cluster headache: methodological issues.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2520386" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Beneficial effect of capsaicin application to the nasal mucosa in cluster headache.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7708405" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Preventative effect of repeated nasal applications of capsaicin in cluster headache.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8495452" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : A double-blind placebo-controlled trial of intranasal capsaicin for cluster headache.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11298668" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Naratriptan prophylactic treatment in cluster headache.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12005276" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Naratriptan in the prophylaxis of cluster headache.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12485208" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Naratriptan in the preventive treatment of cluster headache.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15566418" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Frovatriptan for the treatment of cluster headaches.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8550362" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Preemptive oral treatment with sumatriptan during a cluster period.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8933994" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Melatonin versus placebo in the prophylaxis of cluster headache: a double-blind pilot study with parallel groups.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12390642" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Melatonin as adjunctive therapy in the prophylaxis of cluster headache: a pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12662186" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Parenteral indomethacin (the INDOTEST) in cluster headache.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20656709" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Cluster headache responsive to indomethacin: Case reports and a critical review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12421155" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Treatment of headache with botulinum toxin A--a review according to evidence-based medicine criteria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12421159" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Hyperbaric oxygen treatment of active cluster headache: a double-blind placebo-controlled cross-over study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26391457" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Non-invasive vagus nerve stimulation for PREVention and Acute treatment of chronic cluster headache (PREVA): A randomised controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29231763" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Non-invasive vagus nerve stimulation for the acute treatment of episodic and chronic cluster headache: A randomized, double-blind, sham-controlled ACT2 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20425205" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Deep brain stimulation in cluster headache: hypothalamus or midbrain tegmentum?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20237130" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Anatomical location of effective deep brain stimulation electrodes in chronic cluster headache.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19936616" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Safety and efficacy of deep brain stimulation in refractory cluster headache: a randomized placebo-controlled double-blind trial followed by a 1-year open extension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27029635" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Ventral tegmental area deep brain stimulation for refractory chronic cluster headache.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16832097" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Hypothalamic stimulation for intractable cluster headache: long-term experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32827225" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Deep Brain Stimulation for Chronic Cluster Headache: Meta-Analysis of Individual Patient Data.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15689358" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Hypothalamic stimulation in chronic cluster headache: a pilot study of efficacy and mode of action.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15482354" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Deep brain stimulation for intractable chronic cluster headache: proposals for patient selection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24740514" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Stimulation of the sphenopalatine ganglion in intractable cluster headache: expert consensus on patient selection and standards of care.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23314784" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Stimulation of the sphenopalatine ganglion (SPG) for cluster headache treatment. Pathway CH-1: a randomized, sham-controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27461394" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Cluster headache attack remission with sphenopalatine ganglion stimulation: experiences in chronic cluster headache patients through 24 months.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29349561" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Sphenopalatine ganglion stimulation for cluster headache, results from a large, open-label European registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27165493" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Long-term effectiveness of sphenopalatine ganglion stimulation for cluster headache.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19171831" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Treatment of intractable chronic cluster headache by occipital nerve stimulation in 14 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17362835" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Occipital nerve stimulation for drug-resistant chronic cluster headache: a prospective pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32985662" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Long-Term Efficacy of Occipital Nerve Stimulation for Medically Intractable Cluster Headache.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/38032594" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : The Untold Story of Occipital Nerve Stimulation in Patients With Cluster Headache: Surgical Technique in Relation to Clinical Efficacy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34146510" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Safety and efficacy of occipital nerve stimulation for attack prevention in medically intractable chronic cluster headache (ICON): a randomised, double-blind, multicentre, phase 3, electrical dose-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5506058" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Sphenopalatine gangionectomy for cluster headache.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2401621" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Chronic cluster headache managed by nervus intermedius section.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11749879" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Interventional treatment for cluster headache: a review of the options.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12707445" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Outcome of trigeminal nerve section in the treatment of chronic cluster headache.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17277687" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Trigeminal nerve radiosurgical treatment in intractable chronic cluster headache: unexpected high toxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15654036" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Gamma knife treatment for refractory cluster headache: prospective open trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11960888" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Persistence of attacks of cluster headache after trigeminal nerve root section.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17459083" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Burden of cluster headache.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27694264" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Cluster headache and depression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11839832" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Cluster headache: a prospective clinical study with diagnostic implications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7215402" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Clinical observations on 76 cluster headache cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12485209" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Health-related quality of life in patients with cluster headache during active periods.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17442761" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : Chronic cluster headache: a French clinical descriptive study.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
